Tianda Pharmaceuticals Limited

SEHK:455 Stock Report

Market Cap: HK$397.8m

Tianda Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 4/6

Tianda Pharmaceuticals has a total shareholder equity of HK$544.4M and total debt of HK$91.9M, which brings its debt-to-equity ratio to 16.9%. Its total assets and total liabilities are HK$804.8M and HK$260.3M respectively.

Key information

16.9%

Debt to equity ratio

HK$91.90m

Debt

Interest coverage ration/a
CashHK$103.77m
EquityHK$544.43m
Total liabilitiesHK$260.34m
Total assetsHK$804.77m

Recent financial health updates

Recent updates

Is Tianda Pharmaceuticals (HKG:455) Weighed On By Its Debt Load?

Dec 10
Is Tianda Pharmaceuticals (HKG:455) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

Oct 28
Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16
Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20
Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27
There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Mar 02
Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

May 23
Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Dec 06
Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Jan 11
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Aug 05
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Dec 11
Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

Financial Position Analysis

Short Term Liabilities: 455's short term assets (HK$244.0M) do not cover its short term liabilities (HK$253.1M).

Long Term Liabilities: 455's short term assets (HK$244.0M) exceed its long term liabilities (HK$7.2M).


Debt to Equity History and Analysis

Debt Level: 455 has more cash than its total debt.

Reducing Debt: 455's debt to equity ratio has increased from 0% to 16.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 455 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 455 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 10% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:32
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianda Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jayaprabha DhavaleVirtua Research Inc.